Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02031458 | A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer(BIRCH) | completed | Phase 2 | 667 | Hoffmann-La RocheINDUSTRY | 19 | Jan 6, 2020 | clinicaltrials |
| NCT00290355 | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery | completed | Phase 2 | 182 | GlaxoSmithKlineINDUSTRY | 14 | Jan 2, 2020 |
| clinicaltrials |
| NCT01880528 | Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer | completed | Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00200395 | OSI-774 (Erlotinib, Tarceva) in Elderly Patients | completed | Phase 2 | 30 | Montefiore Medical CenterOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT02047344 | Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC | completed | Phase 2 | 31 | Golden Biotechnology CorporationINDUSTRY | 2 | Dec 26, 2019 | clinicaltrials |
| NCT01813734 | Ponatinib in Advanced NSCLC w/ RET Translocations | completed | Phase 2 | 9 | Massachusetts General HospitalOTHER | 1 | Dec 24, 2019 | clinicaltrials |
| NCT00137839 | Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung | completed | Phase 2 | 84 | Pasi A. Janne, MD, PhDOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00798720 | Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 18 | University of Wisconsin, MadisonOTHER | 0 | Dec 13, 2019 | clinicaltrials |
| NCT03129256 | An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer(EASE) | completed | Phase 2 | 52 | Changzhou Cancer Hospital of Soochow UniversityOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT00563784 | TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT03023423 | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer(DARZALEX) | completed | Phase 1 / Phase 2 | 100 | Janssen Research & Development, LLCINDUSTRY | 5 | Nov 20, 2019 | clinicaltrials |
| NCT00388960 | Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 99 | CelgeneINDUSTRY | 5 | Nov 19, 2019 | clinicaltrials |
| NCT00582634 | Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer | completed | Phase 2 | 4 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02976116 | A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 50 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 15, 2019 | clinicaltrials |
| NCT00274443 | An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin | completed | Phase 2 | 250 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00617409 | To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid | completed | Phase 2 | 69 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01631357 | Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer(CIK) | completed | Phase 2 / Phase 3 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT00771953 | 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer | completed | Phase 2 | 109 | University of Maryland, BaltimoreOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT00375193 | Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy | completed | Phase 2 | 75 | CelgeneINDUSTRY | 3 | Oct 24, 2019 | clinicaltrials |
| NCT00647426 | Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC | completed | Phase 2 | 7 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT03544814 | EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression | completed | Phase 2 | 99 | Shanghai Chest HospitalOTHER | 0 | Oct 15, 2019 | clinicaltrials |
| NCT00483509 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma(NGR007) | completed | Phase 2 | 28 | AGC Biologics S.p.A.INDUSTRY | 1 | Oct 4, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01165021 | A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer | completed | Phase 2 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT00775307 | Adjuvant Pazopanib in Stage I NSCLC | completed | Phase 2 / Phase 3 | 142 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01281124 | Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01232452 | A Study in Non-Small Cell Lung Cancer | completed | Phase 2 | 172 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 20, 2019 | clinicaltrials |
| NCT00349089 | Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy | completed | Phase 2 | 132 | Thoraxklinik-Heidelberg gGmbHOTHER | 3 | Sep 19, 2019 | clinicaltrials |
| NCT01059643 | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01900652 | A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants(Chime) | completed | Phase 2 | 111 | Eli Lilly and CompanyINDUSTRY | 10 | Sep 18, 2019 | clinicaltrials |
| NCT00988858 | A Study of Advanced or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 55 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 17, 2019 | clinicaltrials |
| NCT01025284 | A Study for Participants With Small-Cell Lung Cancer | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 17, 2019 | clinicaltrials |
| NCT01160744 | A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 280 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 13, 2019 | clinicaltrials |
| NCT02448303 | Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer(KEYNOTE166) | completed | Phase 2 | 74 | Acerta Pharma BVINDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02843815 | Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02845856 | Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01107444 | Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 180 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 11, 2019 | clinicaltrials |
| NCT01259089 | Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT01469000 | A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 195 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 10, 2019 | clinicaltrials |
| NCT03228277 | Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA | completed | Phase 2 | 25 | Konkuk University Medical CenterOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT00126581 | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | completed | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01439568 | A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00065182 | Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer | completed | Phase 2 | 399 | GlaxoSmithKlineINDUSTRY | 3 | Jun 24, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT00198367 | Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 120 | Hospices Civils de LyonOTHER | 1 | May 28, 2019 | clinicaltrials |
| NCT00548093 | PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib | completed | Phase 2 | 66 | PfizerINDUSTRY | 1 | May 21, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jan 6, 2020source: clinicaltrials